Substance
ABATACEPT
Global reference: every product and company linked to this substance.
- cas: 332348-12-6
- ncit: C28898
- rxnorm: 614391
- unii: 7D0YB67S97
ABATACEPT (GENETICAL RECOMBINATION) [JAN] · abatacept [INN] · ABATACEPT [JAN] · ABATACEPT [USAN] · Abatacept [WHO-DD] · BMS-188667 · CTLA4-IGG4M · ORENCIA · RG-1046
Revenue by product (2)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK | ORENCIA | Q2 2026 | $1.0B |
| BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK | ORENCIA | Q2 2026 | $1.0B |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (2)
- ORENCIA · BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK
- ORENCIA · BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK